Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock - Currency: USD

0.0786  -0.05 (-39.45%)

After market: 0.0788 +0 (+0.25%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SPRB. SPRB was compared to 555 industry peers in the Biotechnology industry. Both the profitability and financial health of SPRB have multiple concerns. SPRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SPRB has reported negative net income.
In the past year SPRB has reported a negative cash flow from operations.
SPRB had negative earnings in each of the past 5 years.
SPRB had a negative operating cash flow in each of the past 5 years.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of SPRB (-117.31%) is worse than 79.43% of its industry peers.
SPRB has a worse Return On Equity (-184.02%) than 66.49% of its industry peers.
Industry RankSector Rank
ROA -117.31%
ROE -184.02%
ROIC N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

SPRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRB has more shares outstanding
SPRB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SPRB is higher compared to a year ago.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SPRB has an Altman-Z score of -10.85. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
SPRB has a Altman-Z score of -10.85. This is in the lower half of the industry: SPRB underperforms 76.77% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that SPRB is not too dependend on debt financing.
SPRB's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. SPRB outperforms 45.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.85
ROIC/WACCN/A
WACC10.71%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.90 indicates that SPRB has no problem at all paying its short term obligations.
SPRB's Current ratio of 2.90 is on the low side compared to the rest of the industry. SPRB is outperformed by 66.49% of its industry peers.
SPRB has a Quick Ratio of 2.90. This indicates that SPRB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.90, SPRB is doing worse than 64.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.9
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

SPRB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.59%.
The Revenue for SPRB has decreased by -51.31% in the past year. This is quite bad
EPS 1Y (TTM)-1.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.5%
Revenue 1Y (TTM)-51.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.86%

3.2 Future

The Earnings Per Share is expected to grow by 13.56% on average over the next years. This is quite good.
SPRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y54.58%
EPS Next 2Y20.38%
EPS Next 3Y4.69%
EPS Next 5Y13.56%
Revenue Next Year-68.59%
Revenue Next 2Y-81.91%
Revenue Next 3Y26.49%
Revenue Next 5Y-14.87%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SPRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SPRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.38%
EPS Next 3Y4.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (4/28/2025, 8:00:02 PM)

After market: 0.0788 +0 (+0.25%)

0.0786

-0.05 (-39.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners43.66%
Inst Owner Change-5.16%
Ins Owners11.57%
Ins Owner Change0%
Market Cap3.32M
Analysts50
Price Target1.53 (1846.56%)
Short Float %0.09%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-76.4%
Min EPS beat(2)-166.11%
Max EPS beat(2)13.31%
EPS beat(4)3
Avg EPS beat(4)-28.73%
Min EPS beat(4)-166.11%
Max EPS beat(4)32.77%
EPS beat(8)6
Avg EPS beat(8)-5.91%
EPS beat(12)9
Avg EPS beat(12)-2.03%
EPS beat(16)12
Avg EPS beat(16)0.92%
Revenue beat(2)0
Avg Revenue beat(2)-41.64%
Min Revenue beat(2)-60.5%
Max Revenue beat(2)-22.79%
Revenue beat(4)2
Avg Revenue beat(4)-2.05%
Min Revenue beat(4)-60.5%
Max Revenue beat(4)69.52%
Revenue beat(8)6
Avg Revenue beat(8)79.98%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.18%
PT rev (3m)-18.18%
EPS NQ rev (1m)-17.11%
EPS NQ rev (3m)-17.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-20%
Revenue NY rev (1m)-20%
Revenue NY rev (3m)-20%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 0.12
P/tB 0.12
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0.12
BVpS0.68
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.31%
ROE -184.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.9
Quick Ratio 2.9
Altman-Z -10.85
F-Score2
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.5%
EPS Next Y54.58%
EPS Next 2Y20.38%
EPS Next 3Y4.69%
EPS Next 5Y13.56%
Revenue 1Y (TTM)-51.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.86%
Revenue Next Year-68.59%
Revenue Next 2Y-81.91%
Revenue Next 3Y26.49%
Revenue Next 5Y-14.87%
EBIT growth 1Y-8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-68.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.19%
OCF growth 3YN/A
OCF growth 5YN/A